PTPRC and neoplasm: FACS analysis revealed that combination treatment remarkably reduced tumor burden, reflected by significantly less human CD45+ cells in murine bone marrow (BM, Fig. 7c), spleen (SP, Fig. 7d), and peripheral blood (PB, Fig. 7e).